Chengdu Easton Biopharmaceuticals Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 34.30%

Chengdu Easton Biopharmaceuticals Co Ltd (688513) has an Asset Resilience Ratio of 34.30% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See financial agility of Chengdu Easton Biopharmaceuticals Co Ltd to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

CN¥1.30 Billion
≈ $189.58 Million USD Cash + Short-term Investments

Total Assets

CN¥3.78 Billion
≈ $552.76 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Chengdu Easton Biopharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. See 688513 equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Chengdu Easton Biopharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Chengdu Easton Biopharmaceuticals Co Ltd worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.30 Billion 34.3%
Total Liquid Assets CN¥1.30 Billion 34.30%

Asset Resilience Insights

  • Very High Liquidity: Chengdu Easton Biopharmaceuticals Co Ltd maintains exceptional liquid asset reserves at 34.30% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Chengdu Easton Biopharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio

Compare Chengdu Easton Biopharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
Biotechnology 6.52%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

Annual Asset Resilience Ratio for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Chengdu Easton Biopharmaceuticals Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 19.96% CN¥758.00 Million
≈ $110.92 Million
CN¥3.80 Billion
≈ $555.75 Million
+6.65pp
2024-12-31 13.30% CN¥452.35 Million
≈ $66.19 Million
CN¥3.40 Billion
≈ $497.55 Million
-8.86pp
2023-12-31 22.16% CN¥741.78 Million
≈ $108.55 Million
CN¥3.35 Billion
≈ $489.74 Million
+5.05pp
2022-12-31 17.11% CN¥516.36 Million
≈ $75.56 Million
CN¥3.02 Billion
≈ $441.56 Million
+0.76pp
2021-12-31 16.35% CN¥453.84 Million
≈ $66.41 Million
CN¥2.78 Billion
≈ $406.11 Million
-6.17pp
2020-12-31 22.52% CN¥570.00 Million
≈ $83.41 Million
CN¥2.53 Billion
≈ $370.34 Million
+21.34pp
2013-12-31 1.18% CN¥3.00 Million
≈ $438.99K
CN¥254.86 Million
≈ $37.29 Million
--
pp = percentage points

About Chengdu Easton Biopharmaceuticals Co Ltd

SHG:688513 China Biotechnology
Market Cap
$1.16 Billion
CN¥7.95 Billion CNY
Market Cap Rank
#8407 Global
#2063 in China
Share Price
CN¥45.01
Change (1 day)
+2.76%
52-Week Range
CN¥39.30 - CN¥79.60
All Time High
CN¥79.60
About

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; A… Read more